Charles River Laboratories Intl. Inc vs W W Grainger Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while W W Grainger Inc trades at $1,289.35 (market cap $59.76B). The key difference: W W Grainger Inc is far larger — about 4.2× Charles River Laboratories Intl. Inc's market cap, and W W Grainger Inc pays a 0.79% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and W W Grainger Inc for 25 Days on average.
| CRL | GWW | |
|---|---|---|
Market Cap | $14.23B | $59.76B |
Volume | 1,176,885 | 186,697 |
Sector | Health | Industrials |
52-Week High | $310.77 | $1.40K |
52-Week Low | $149.93 | $918.18 |
Typical Hold Time | 33 Days | 25 Days |
Enterprise Value | $17.06B | $61.96B |
Dividend Yield | — | 0.79% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
W.W. Grainger (GWW) trades at $1,263.51, down 0.94% on the day, amid a bearish technical signal. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. The company maintains strong profitability with a net income margin of 9.92% and ROE of 47.92%, though valuation ratios like P/E of 32.34 appear elevated. Recent news highlights institutional buying and expansion efforts, including a new distribution center in Oregon and the acquisition of technology assets from Adroit Worldwide Media.
The outlook for GWW is cautiously optimistic, supported by earnings beats and solid fundamentals, but risks include high valuation and competitive pressures. Analyst consensus leans hold with a $1,310 price target, suggesting limited upside. Investors should weigh strong cash flow and dividend consistency against potential margin compression and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →